Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 276.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,812 shares of the biopharmaceutical company’s stock after acquiring an additional 24,102 shares during the quarter. SG Americas Securities LLC’s holdings in Catalyst Pharmaceuticals were worth $685,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Sei Investments Co. boosted its holdings in Catalyst Pharmaceuticals by 1.3% in the 2nd quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company’s stock valued at $1,308,000 after purchasing an additional 1,098 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 87.1% in the 2nd quarter. AQR Capital Management LLC now owns 488,386 shares of the biopharmaceutical company’s stock valued at $7,565,000 after buying an additional 227,321 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Catalyst Pharmaceuticals by 25.3% in the second quarter. The Manufacturers Life Insurance Company now owns 64,738 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 13,054 shares in the last quarter. Mackenzie Financial Corp acquired a new position in Catalyst Pharmaceuticals during the second quarter worth $217,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Catalyst Pharmaceuticals during the second quarter worth $258,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $23.19 on Friday. The stock’s 50 day moving average price is $21.96 and its 200 day moving average price is $20.65. The firm has a market cap of $2.77 billion, a P/E ratio of 19.65, a PEG ratio of 2.28 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 1 year low of $13.12 and a 1 year high of $24.64.

Insider Buying and Selling

In other news, insider Gary Ingenito sold 12,000 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. This trade represents a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

CPRX has been the subject of a number of recent analyst reports. Stephens started coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Bank of America restated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Truist Financial lifted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, HC Wainwright boosted their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $32.86.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.